Get the Stockscreener App
9.115
4.30%
0.385
Nektar Therapeutics stock is traded at $9.115, with a volume of 112.02K.
It is up +4.30% in the last 24 hours and up +1,229% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$8.73
Open:
$8.67
24h Volume:
112.02K
Relative Volume:
0.06
Market Cap:
$140.82M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-6.2432
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-4.66%
1M Performance:
+1,229%
6M Performance:
+884.22%
1Y Performance:
+698.68%
1-Day Range:
$8.565
$9.273
1-Week Range:
$7.99
$9.71
52-Week Range:
$0.432
$11.65
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
9.155 | 140.82M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.88 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
517.77 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.55 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.29 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.58 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Alopecia Areata Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart.com
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC (NKTR) - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN
Nektar (NKTR) Trading Paused Ahead of Important Announcement | N - GuruFocus
Nektar Therapeutics Increases Authorized Shares To 390 Million - marketscreener.com
Nektar Therapeutics Approves Reverse Stock Split - TipRanks
Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com
BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire
Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq
Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World
What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st
Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World
GSK’s liver asset play grows group of $1B upfront deals - biocentury.com
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance
Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World
Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks
H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target By Investing.com - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World
Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com
H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India
Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st
NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView
BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus
Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks
Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nektar Therapeutics Stock (NKTR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | Chief Legal Officer |
May 19 '25 |
Sale |
0.67 |
9,996 |
6,697 |
314,296 |
| ROBIN HOWARD W | President & CEO |
May 19 '25 |
Sale |
0.67 |
23,208 |
15,549 |
1,063,693 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):